Cure My Disease

Don't miss your cure!

 Log in / Sign up

Sabatolimab safety tracked in extended cancer study

NCT ID NCT05201066

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This study looks at the long-term safety of the drug sabatolimab in people with myelodysplastic syndromes or chronic myelomonocytic leukemia who already benefited from it in a previous trial. About 33 participants will continue treatment and be monitored for side effects. The goal is to gather more safety information, not to test if the drug works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
sabatolimab (a cancer immunotherapy drug, given as an infusion)
What this could lead to
If successful, this study could show that long-term sabatolimab is safe for people with certain blood cancers, supporting its continued use.
What could go wrong
This is a small, early-phase safety study with only 33 participants, so results may not apply to everyone. It does not test whether the drug works better than other options.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEUKEMIA, MYELOMONOCYTIC, CHRONIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic myelomonocytic leukemia myelodysplastic syndrome Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LEUKEMIA, MYELOMONOCYTIC, CHRONIC MYELODYSPLASTIC SYNDROMES

Contacts and locations

Locations

  • Huntsman Cancer Institute Univ of Utah

    Salt Lake City, Utah, 84112 0550, United States

  • Novartis Investigative Site

    Clayton, Victoria, 3168, Australia

  • Novartis Investigative Site

    Florianópolis, Santa Catarina, 88020-210, Brazil

  • Novartis Investigative Site

    Vancouver, British Columbia, V5Z 1M9, Canada

  • Novartis Investigative Site

    Changchun, Jilin, 130021, China

  • Novartis Investigative Site

    Tianjin, 300020, China

  • Novartis Investigative Site

    Prague, 128 08, Czechia

  • Novartis Investigative Site

    Toulouse, 31059, France

  • Novartis Investigative Site

    Freiburg im Breisgau, Baden-Wurttemberg, 79106, Germany

  • Novartis Investigative Site

    Alexandroupoli, 681 00, Greece

  • Novartis Investigative Site

    Pátrai, 265 04, Greece

  • Novartis Investigative Site

    Brescia, BS, 25123, Italy

  • Novartis Investigative Site

    Florence, FI, 50134, Italy

  • Novartis Investigative Site

    Genova, GE, 16132, Italy

  • Novartis Investigative Site

    Milan, MI, 20162, Italy

  • Novartis Investigative Site

    Roma, RM, 00133, Italy

  • Novartis Investigative Site

    Fukushima, 9601295, Japan

  • Novartis Investigative Site

    Kuala Lumpur, 59100, Malaysia

  • Novartis Investigative Site

    Badalona, Barcelona, 08916, Spain

  • Novartis Investigative Site

    Barcelona, 08036, Spain

  • Novartis Investigative Site

    Madrid, 28009, Spain

  • Novartis Investigative Site

    Zurich, 8091, Switzerland

  • Novartis Investigative Site

    Izmir, 35100, Turkey (Türkiye)

  • Oregon Health Sciences University

    Portland, Oregon, 97239, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.